OQROGet OQRO Pro
Insider trade

Insight Molecular Diagnostics (IMDX)10% owner bought ~$352K

BROADWOOD PARTNERS, 10% owner at Insight Molecular Diagnostics, bought ~$352K of Insight Molecular Diagnostics shares.

~$352K
Approx. value · 102K sh @ $3.45
12M
Holds after · shares reported
Traded
Apr 16, 2026
Filed
Apr 20, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 20, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  2. Mar 26, 2026Company filing · Form 8-K · ResultsReported its results
  3. Apr 16, 2026 · this disclosureInsider10% owner purchased ~$352K of IMDX shares in the open market

What came next

  1. Apr 17, 2026Insider10% owner purchased ~$143K of IMDX shares in the open market
  2. Apr 20, 2026Insider10% owner purchased ~$158K of IMDX shares in the open market
  3. Apr 23, 2026Insider10% owner purchased ~$982K of IMDX shares in the open market
  4. Apr 24, 2026Insider10% owner purchased ~$137K of IMDX shares in the open market
  5. Apr 27, 2026Insider10% owner purchased ~$913K of IMDX shares in the open market
  6. May 13, 2026Company filing · Form 8-K · ResultsReported its results
  7. Jun 11, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As reported below under Item 5.07 of this report, Insight Molecular Diagnostics Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2026, at which the Company’s shareholders approved an amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan (as previously amended, the “Incentive Plan”) to provide for an additional 1,750,000 shares of the Company’s…”
  8. Aug 10, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors (and 1 more item)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Insight Molecular Diagnostics

OQRO holds no insider, Congress, fund or contract record for Insight Molecular Diagnostics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IMDX page.

Other recent filings by BROADWOOD PARTNERS, L.P., 10% owner

The full history of BROADWOOD PARTNERS, L.P., 10% owner is on the profile page.

How this filing works

Other disclosures at Insight Molecular Diagnostics

Everything OQRO holds on this company is on its IMDX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data